COVID-19 pandemic increased rates and severity of depression, whether people were infected or not

Intermountain Healthcare

 

Salt Lake City, USA (March 4, 2023) — The COVID-19 pandemic impacted just about every part of people’s lives. Quarantining, social distancing, societal disruptions and an ever-shifting, uncertain landscape of rules and restrictions and variants created stress and isolation that impacted the mental health of millions of Americans.

Now, in a new study of nearly 136,000 patients from Intermountain Health in Salt Lake City, researchers found that depressive symptoms and severity of depression was significant among all patients in the study, regardless of whether they were infected with COVID-19 or not.

In the study, results of which were presented at the American College of Cardiology’s 2023 scientific session in New Orleans on March 4, Intermountain researchers found that depression symptoms rose significantly during the pandemic, with more than half of all patients reporting some degree of clinically-relevant depressive symptoms.

“It didn’t matter if a patient was positive or negative for the virus. We found increased rates of depression and depression severity across the board,” said Heidi T. May, PhD, cardiovascular epidemiologist at Intermountain Health and principal investigator of the study. “As poor mental health can impact chronic diseases, including cardiovascular disease, screening for and treating mental health is a critical part of any overall patient care process right now. Doing so will both help patients in this moment, and protect their future health.”

In the Intermountain study, researchers examined 135,864 patients who completed their first Patient Healthcare Questionnare-9 (PHQ-9), which is used to screen for depression, in a primary care setting from January 1, 2016, to April 20, 2022.

They then looked at how those scores, which categorize patients’ depression into none (<10), mild (10-14), moderate (15-19) and severe (>20), over time.

The researchers found a significant increase in PHQ-9 scores, with the mean PHQ-9 score rising by 1.5 points.

They also found that before the pandemic, about 45% of patients reported some degree of depression. Starting in 2021, that changed to 55% of patients showing at least some degree of depression. There was no significant difference in scores among COVID positive and negative patients.

Depression, anxiety, stress, and PTSD are linked to higher rates of high blood pressure and higher levels of cortisol, which can lead to calcium buildup in the arteries, metabolic disease, and heart disease, according to the CDC.

“We know depression is a risk factor for chronic disease, so given these findings, it’s really important to mitigate some of the effects of depression so these patients can lead healthier and happier lives right now, and in the future,” said Dr. May.

 

 

Image: A new study of nearly 136,000 patients from Intermountain Health in Salt Lake City found that depressive symptoms and severity of depression was significant among all patients in the study examing impact of COVID-19 pandemic, regardless of whether they were infected with COVID-19 or not.  Credit: Intermountain Health

 

 

 

Method of Research: Observational study

Subject of Research: People

 

 


Intermountain Healthcare, 04.03.2023 (tB).

Schlagwörter: , , ,

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…